⌕
Insmed · INSM · Nasdaq
Tenet 33 · Weak
Compare
$121.86−0.83%At closeTenet 33 · Weak
$121.86−1.02 (−0.83%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$119.48−2.38 (−1.95%)
After hours: Nov 17, 2026, 5:11 PM ET

Insmed (INSM) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~33.9%/yr (FY21→FY25), net margin −210.5%. Worth your attention in FY25: Share count (+77.5%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲66.7%
606.4
FY21→FY25CAGR +33.9%/yr
Net income ($M)▼39.7%
−1,276.8
FY21→FY25CAGR —
Free cash flow ($M)▼37.1%
−967.6
FY21→FY25CAGR —
Diluted EPS▼15.3%
−6.42
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+77.5%

112.1mn → 199.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$32.6M

+48.5% YoY in FY25 · 5.4% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)606.4Revenue−122.9COGS483.5Gross profit−771.1R&D−701.2SG&A−1246.8Op income−30.0Tax & other−1276.8Net income

-211¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~3%FY21FY25

Over this window: gross 76.6% → 79.7%. Net margin -210.5% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
1,519.7606.4363.7305.2245.4188.5▲66.7%+33.9%
Cost of revenue
237.1122.985.765.655.144.2▲43.4%+29.2%
Gross profit
1,282.7483.5278.0239.6190.2144.3▲73.9%+35.3%
Research & development
944.4771.1598.4571.0397.5272.7▲28.9%+29.7%
Selling, general & admin
960.2701.2461.1344.5265.8234.3▲52.1%+31.5%
Total operating expenses
1,846.61,730.31,156.2949.3647.6519.4▲49.6%+35.1%
Operating incomefeeds ROC rank
−564.0−1,246.8−878.3−709.6−457.3−375.1▼42.0%—
Other income, net
−34.1−25.0−31.8−37.4−22.8−61.3——
Pretax income
−598.1−1,271.7−910.1−747.0−480.2−436.4▼39.7%—
Income tax
7.65.03.72.61.4−1.8▲35.6%+53.7% (22→25)
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−605.6−1,276.8−913.8−749.6−481.5−434.7▼39.7%—
Per share
Diluted EPSbuyback-sensitive
−2.83−6.42−5.57−5.34−3.91−3.88▼15.3%—
Diluted shares (mn)
218.79199.01164.04140.43123.03112.11▲21.3%+15.4%
Margins
Gross margin78th pct in Healthcare
84.4%79.7%76.4%78.5%77.5%76.6%▲3.3pp+3.2pp
Operating margin
−37.1%−205.6%−241.5%−232.5%−186.4%−199.0%▲35.9pp−6.6pp
Net margin16th pct in Healthcare
−39.9%−210.5%−251.2%−245.6%−196.3%−230.6%▲40.7pp+20.1pp
† TTM = trailing four quarters through 2026-09-30.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Insmed's revenue last fiscal year?

Insmed reported revenue of $606.4M in fiscal 2025, up 66.7% from fiscal 2024.

What was Insmed's net income?

Insmed reported net income of −$1,276.8M in fiscal 2025, a net margin of −210.5%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.